ERBB2 and breast cancer: Similarly, in a phase Ib study investigating Trastuzumab Duocarmazine in patients with advanced solid tumors, ORR was 28% and 40% in the HR + HER2-low and triple-negative HER2-low breast cancer cohorts, respectively11.